The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases
Open accessAbstract
BACKGROUND: Amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) mutations cause autosomal dominant forms of early-onset Alzheimer disease (AD-EOAD). Although these genes were identified in the 1990s, variant classification remains a challenge, highlighting the need to colligate mutations from large series. METHODS AND FINDINGS: We report here a novel update (2012-2016) of the genetic screening of the large AD-EOAD series ascertained across 28 French hospitals from 1993 onwards, bringing the total number of families with identified mutations to n = 170. Families were included when at least two first-degree relatives suffered from early-onset Alzheimer disease (EOAD) with an age of onset (AOO) ≤65 y in two generations. Furthermore, we also screened 129 sporadic cases of Alzheimer disease with an AOO below age 51 (44% males, mean AOO = 45 ± 2 y). APP, PSEN1, or PSEN2 mutations were identified in 53 novel AD-EOAD families. Of the 129 sporadic cases screened, 17 carried a PSEN1 mutation and 1 carried an APP duplication (13%). Parental DNA was available for 10 sporadic mutation carriers, allowing us to show that the mutation had occurred de novo in each case. Thirteen mutations (12 in PSEN1 and 1 in PSEN2) identified either in familial or in sporadic cases were previously unreported. Of the 53 mutation carriers with available cerebrospinal fluid (CSF) biomarkers, 46 (87%) had all three CSF biomarkers-total tau protein (Tau), phospho-tau protein (P-Tau), and amyloid β (Aβ)42-in abnormal ranges. No mutation carrier had the three biomarkers in normal ranges. One limitation of this study is the absence of functional assessment of the possibly and probably pathogenic variants, which should help their classification. CONCLUSIONS: Our findings suggest that a nonnegligible fraction of PSEN1 mutations occurs de novo, which is of high importance for genetic counseling, as PSEN1 mutational screening is currently performed in familial cases only. Among the 90 distinct mutations found in the whole sample of families and isolated cases, definite pathogenicity is currently established for only 77%, emphasizing the need to pursue the effort to classify variants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in PS1 and PS2 primarily alter APP γ-cleavage, thereby resulting in a decreased Aβ40/42 ratio.”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [37]
In the citing paper
“Although causal variants in these genes are typically thought to be inherited in an autosomal dominant fashion, de novo variants in APP, PSEN1, and PSEN2 have also been identified by sequencing in sporadic cases of EOAD that occur with no family history of disease [158, 159].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [158]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Rovelet‐Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin‐Njock, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,284
Self-citationChartier-Harlin, M.-C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., Hardy, J., et al. (1991) · Nature · doi:10.1038/353844a0 · Cited by 1,214
Trafficking and Proteolytic Processing of APP
Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006270 · Cited by 1,075
A framework for the interpretation of de novo mutation in human disease
Samocha, K. E., Robinson, E. B., Sanders, S. J., Stevens, C., Sabo, A., McGrath, L. M., Kosmicki, J. A., Rehnström, K., Mallick, S., Kirby, A., et al. (2014) · Nature Genetics · doi:10.1038/ng.3050 · Cited by 979
A Familial Alzheimer's Disease Locus on Chromosome 1
Levy‐Lahad, E., Wijsman, E. M., Nemens, E. J., Anderson, L., Goddard, K. A. B., Weber, J. L., Bird, T. D., & Schellenberg, G. D. (1995) · Science · doi:10.1126/science.7638621 · Cited by 832
Cited by
Sorted by citations
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases
Cabral-Pacheco, G. A., Garza-Veloz, I., Castruita-De la Rosa, C., Ramirez-Acuña, J. M., Perez-Romero, B. A., Guerrero-Rodriguez, J. F., Martinez-Avila, N., & Martinez-Fierro, M. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249739 · Cited by 1,820
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z., Anderson, C. A. M., Arora, P. K., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,284
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
Schwartzentruber, J., Cooper, S., Liu, J. Z., Barrio-Hernandez, I., Bello, E., Kumasaka, N., Young, A. M. H., Franklin, R. J. M., Johnson, T., Estrada, K., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00776-w · Cited by 532
González-Reyes, R. E., Nava-Mesa, M. O., Vargas-Sánchez, K., Ariza-Salamanca, D. F., & Mora-Muñoz, L. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00427 · Cited by 541
Endoplasmic Reticulum Stress and Unfolded Protein Response in Neurodegenerative Diseases
Ghemrawi, R., & Khair, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176127 · Cited by 415
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Tryphena, K. P., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 438
Bisht, K., Sharma, K. P., & Tremblay, M. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.05.003 · Cited by 366
Microglia Phenotypes in Aging and Neurodegenerative Diseases
Wendimu, M. Y., & Hooks, S. B. (2022) · Cells · doi:10.3390/cells11132091 · Cited by 336
Alzheimer’s Disease: An Updated Overview of Its Genetics
Andrade-Guerrero, J., Santiago-Balmaseda, A., Jeronimo-Aguilar, P., Vargas-Rodríguez, I., Cadena-Suárez, A. R., Sánchez-Garibay, C., Pozo-Molina, G., Méndez-Catalá, C. F., Cardenas-Aguayo, M.-D.-C., Diaz-Cintra, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043754 · Cited by 336
Monteiro, A. R., Barbosa, D. J., Remião, F., & Silva, R. V. D. S. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115522 · Cited by 375
Palaniappan, L. P., Allen, N. B., Almarzooq, Z., Anderson, C. A. M., Arora, P. K., Avery, C. L., Baker-Smith, C. M., Bansal, N., Currie, M. E., Earlie, R. S., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001412 · Cited by 343
Morris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
Effects of curcumin on mitochondria in neurodegenerative diseases
Bagheri, H., Ghasemi, F., Barreto, G. E., Rafiee, R., Sathyapalan, T., & Sahebkar, A. (2019) · BioFactors · doi:10.1002/biof.1566 · Cited by 211
Updates in Alzheimer's disease: from basic research to diagnosis and therapies
Liu, E., Zhang, Y., & Wang, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00432-x · Cited by 241
Interplay between MicroRNAs and Oxidative Stress in Neurodegenerative Diseases
Konovalova, J., Gerasymchuk, D., Parkkinen, I., Chmielarz, P., & Domanskyi, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236055 · Cited by 204
Alzheimer’s Disease: The Link Between Amyloid-β and Neurovascular Dysfunction
Solis, E., Hascup, K. N., & Hascup, E. R. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200473 · Cited by 192
Vascular contributions to Alzheimer's disease
Eisenmenger, L. B., Peret, A., Famakin, B. M., Spahic, A., Roberts, G. S., Bockholt, J. H., Johnson, K. M., & Paulsen, J. S. (2022) · Translational research · doi:10.1016/j.trsl.2022.12.003 · Cited by 183
Periodontal microorganisms and Alzheimer disease – A causative relationship?
Jungbauer, G., Stähli, A., Zhu, X., Auber Alberi, L., Sculean, A., & Eick, S. (2022) · Periodontology 2000 · doi:10.1111/prd.12429 · Cited by 174
Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00339 · Cited by 170
Bavisotto, C. C., Scalia, F., Marino, A., Carlisi, D., Bucchieri, F., de Macario, E. C., Macario, A. J. L., Cappello, F., & Campanella, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020434 · Cited by 169
A global view of the genetic basis of Alzheimer disease
Reitz, C., Pericak‐Vance, M. A., Foroud, T., & Mayeux, R. P. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00789-z · Cited by 181
The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer’s Disease
Kloske, C. M., & Wilcock, D. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00754 · Cited by 152
Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease
Sirkis, D. W., Bonham, L. W., Johnson, T. P., La Joie, R., & Yokoyama, J. S. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01531-9 · Cited by 151
Zhou, J., Yu, W., Zhang, M., Tian, X., Li, Y., & Lü, Y. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02748-x · Cited by 139
Burns, D. K., Alexander, R. C., Welsh-Bohmer, K. A., Culp, M., Chiang, C., O’Neil, J., Evans, R. M., Harrigan, P., Plassman, B. L., Burke, J. R., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00043-0 · Cited by 130
Genetic architecture of Alzheimer's disease
Neuner, S. M., TCW, J., & Goate, A. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104976 · Cited by 126
“…in these genes are typically thought to be inherited in an autosomal dominant fashion, de novo variants in APP, PSEN1, and PSEN2 have also been identified by sequencing in sporadic cases of EOAD that occur with no family history of disease (Lanoiselee et al., 2017; Rovelet-Lecrux et al., 2015).”
BackgroundPetit, D., Fernández, S. G., Zoltowska, K. M., Enzlein, T., Ryan, N. S., O’Connor, A., Szaruga, M., Hill, E., Vandenberghe, R. R., Fox, N. C., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01518-6 · Cited by 116
Genetics, Functions, and Clinical Impact of Presenilin-1 (PSEN1) Gene
Bagaria, J., Bagyinszky, E., & An, S. S. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810970 · Cited by 125
Endothelial Mitochondrial Dysfunction in Cerebral Amyloid Angiopathy and Alzheimer’s Disease
Parodi‐Rullán, R. M., Sone, J. Y., & Fossati, S. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190357 · Cited by 110
Perspectives and challenges in patient stratification in Alzheimer’s disease
Abdelnour, C., Agosta, F., Bozzali, M., Fougère, B., Iwata, A., Nilforooshan, R., Takada, L. T., Viñuela, F., & Traber, M. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01055-y · Cited by 108
Velasco‐Estevez, M., Mampay, M., Boutin, H., Chaney, A. M., Warn, P. A., Sharp, J., Burgess, E., Moeendarbary, E., Dev, K. K., & Sheridan, G. K. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00332 · Cited by 105
Fleitas, C., Piñol‐Ripoll, G., Marfull‐Oromí, P., Rocandio, D., Ferrer, I., Rampon, C., Egea, J., & Espinet, C. (2018) · Molecular Brain · doi:10.1186/s13041-018-0411-6 · Cited by 104
Mullane, K., & Williams, M. J. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113945 · Cited by 109
Pathological Changes of Tau Related to Alzheimer’s Disease
Chu, D., & Liu, F. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00457 · Cited by 106
The cellular model for Alzheimer's disease research: PC12 cells
Xie, D., Deng, T., Zhai, Z., Sun, T., & Xu, Y. D. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1016559 · Cited by 107
Stress-Induced Depression and Alzheimer’s Disease: Focus on Astrocytes
Dolotov, O. V., Inozemtseva, L. S., Myasoedov, N. F., & Grivennikov, I. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094999 · Cited by 104
Xiao, X., Liu, H., Liu, X., Zhang, W., Zhang, S., & Jiao, B. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.695808 · Cited by 99
Alzheimer’s disease as type 3 diabetes: understanding the link and implications
Kciuk, M., Kruczkowska, W., Gałęziewska, J., Wanke, K., Kałuzińska-Kołat, Ż., Aleksandrowicz, M., & Kontek, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211955 · Cited by 98
Long, H., Zhou, Z.-W., Cheng, Y., Luo, H., Li, F., Xu, S., & Gao, L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.888989 · Cited by 100
Nand, S., Tiwari, N. K., Singh, P., Mishra, D., Singh, A. K., Hooshmandi, E., Vamanu, E., & Singh, M. P. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.777347 · Cited by 96
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Kwon, S., Iba, M., Kim, C., & Masliah, E. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00853-2 · Cited by 97
Dementia and aging populations—A global priority for contextualized research and health policy
Brayne, C., & Miller, B. L. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002275 · Cited by 93
Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease
Hunter, S., & Brayne, C. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.218 · Cited by 94
Apolipoprotein E4 and meningeal lymphatics in Alzheimer disease: a conceptual framework
Mentis, A. A., Dardiotis, E., & Chrousos, G. P. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0731-7 · Cited by 83
Suresh, S., Ankul Singh, S., Rushendran, R., Vellapandian, C., & Prajapati, B. G. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1303111 · Cited by 93
Pathological mechanisms and treatment progression of Alzheimer’s disease
Zhang, J., Kong, G., Yang, J., Pang, L., & Li, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-02886-9 · Cited by 111
Sirtuin 1 and Alzheimer's disease: An up-to-date review
Rizzi, L., & Roriz‐Cruz, M. (2018) · Neuropeptides · doi:10.1016/j.npep.2018.07.001 · Cited by 84
Colligris, P., de Lara, M. J. P., Colligris, B., & Pintor, J. J. (2018) · Journal of Ophthalmology · doi:10.1155/2018/8538573 · Cited by 84
Fenoglio, C., Scarpini, E. A., Serpente, M., & Galimberti, D. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170702 · Cited by 89
PSEN1, PSEN2, and APP mutations in 404 Chinese pedigrees with familial Alzheimer's disease
Jia, L., Fu, Y., Shen, L., Zhang, H., Zhu, M., Qiu, Q., Wang, Q., Yan, X., Kong, C., Hao, J., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12005 · Cited by 82
Somatic variants in autosomal dominant genes are a rare cause of sporadic Alzheimer’s disease
Nicolas, G., Acuña‐Hidalgo, R., Keogh, M. J., Quenez, O., Steehouwer, M., Lelieveld, S., Rousseau, S., Richard, A., Oud, M. S., Marguet, F., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.3056 · Cited by 81
Self-citationMicrovascular Alterations in Alzheimer's Disease
Steinman, J., Sun, H., & Feng, Z. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.618986 · Cited by 85
The Links between Cardiovascular Diseases and Alzheimer's Disease
Leszek, J., Вячеславовна, М. Е., Belousov, D. M., Koutsouraki, E., Szczechowiak, K., Kobusiak−Prokopowicz, M., Mysiak, A., Diniz, B. S., Somasundaram, S. G., Kirkland, C. E., et al. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200729093724 · Cited by 93
Yang, W., Wang, P., Xu, S., Wang, T., Luo, M., Cai, Y., Xu, C., Xue, G., Que, J., Ding, Q., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51329-2 · Cited by 85
Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction
Zhou, X., Chen, Y., Ip, F. C. F., Jiang, Y., Cao, H., Lv, G., Zhong, H., Chen, J., Tao, Y., Chen, Y., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00269-x · Cited by 79
Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer’s Disease
Pradeepkiran, J. A., Baig, J., Islam, M. A., Kshirsagar, S., & Reddy, P. H. (2024) · Aging and Disease · doi:10.14336/ad.2024.0286 · Cited by 87
Targeting autophagy in Alzheimer’s disease: Animal models and mechanisms
Zhang, X.-W., 澳门大学中华医药研究院中药质量研究国家重点实验室, 澳. 凼. 9., State Key Laboratory of Quality Research in Chinese Medicine, I. O. C. M. S., Zhu, X.-X., Tang, D.-S., Lu, J.-H., 佛山大学广东省动物分子设计与精准育种重点实验室, 广., & Guangdong Provincial Key Laboratory of Animal Molecular Design and Precise Breeding, G. E. T. C. O. G. P. (2023) · Zoological Research · doi:10.24272/j.issn.2095-8137.2023.294 · Cited by 77
New pathogenic insights from large animal models of neurodegenerative diseases
Yin, P., Li, S., Li, X., & Yang, W. (2022) · Protein & Cell · doi:10.1007/s13238-022-00912-8 · Cited by 79
Johnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73
Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies
Martinelli, A. H. S., Lopes, F. C., John, E. B. D. O., Carlini, C. R., & Ligabue‐Braun, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061322 · Cited by 99
Benchmarking machine learning models for late-onset alzheimer’s disease prediction from genomic data
De Velasco Oriol, J., Vallejo, E. E., Estrada, K., Taméz Peña, J. G., & Disease Neuroimaging Initiative, T. A. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3158-x · Cited by 71
Wang, W., Corominas, R., & Lin, G. N. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00258 · Cited by 70
Integrated communications between cyclooxygenase‐2 and Alzheimer's disease
Guan, P.-P., & Wang, P. (2018) · The FASEB Journal · doi:10.1096/fj.201800355rrrr · Cited by 70
“Amyloid‐beta accumulation cycle” as a prevention and/or therapy target for Alzheimer's disease
Rao, C. V., Asch, A. S., Carr, D. J. J., & Yamada, H. Y. (2020) · Aging Cell · doi:10.1111/acel.13109 · Cited by 69
Modeling neurodegenerative disorders in zebrafish
Bashirzade, A. A., Zabegalov, K. N., Volgin, A. D., Belova, A. S., Demin, K. A., de Abreu, M. S., Babchenko, V. Y., Bashirzade, K. A., Yenkoyan, K. B., Tikhonova, M. A., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104679 · Cited by 71
APP, PSEN1, and PSEN2 Mutations in Asian Patients with Early-Onset Alzheimer Disease
Giau, V. V., Bagyinszky, E., Youn, Y. C., An, S. S. A., & Kim, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194757 · Cited by 68
The role of CD2AP in the Pathogenesis of Alzheimer's Disease
Tao, Q.-Q., Chen, Y.-C., & Wu, Z.-Y. (2019) · Aging and disease · doi:10.14336/ad.2018.1025 · Cited by 61
Babu, R. O., Lui, V. C. H., Chen, Y., Yiu, R. S. W., Ye, Y., Niu, B., Wu, Z., Zhang, R., Yu, M., Chung, B., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.012 · Cited by 65
Recent Progress in the Pharmacotherapy of Alzheimer’s Disease
Khoury, R., Patel, K., Gold, J., Hinds, S., & Grossberg, G. T. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0499-x · Cited by 62
Epigenetic signatures of methylated DNA cytosine in Alzheimer’s disease
Fetahu, I. S., Ma, D., Rabidou, K., Argueta, C. E., Smith, M., Liu, H., Wu, F., & Shi, Y. G. (2019) · Science Advances · doi:10.1126/sciadv.aaw2880 · Cited by 60
Prasanth, M. I., Sivamaruthi, B. S., Cheong, C. S. Y., Verma, K., Tencomnao, T., Brimson, J. M., & Prasansuklab, A. (2024) · Antioxidants · doi:10.3390/antiox13050606 · Cited by 65
Blood-Based Biomarkers in Alzheimer’s Disease: Advancing Non-Invasive Diagnostics and Prognostics
Dhauria, M., Mondal, R., Deb, S., Shome, G., Chowdhury, D., Sarkar, S., & Benito‐León, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010911 · Cited by 62
Venkataraman, L., Fair, S. R., McElroy, C. A., Hester, M. E., & Fu, H. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10068-9 · Cited by 55
Cerebral Small Vessel Disease in Sporadic and Familial Alzheimer Disease
Kalaria, R. N., & Falla, D. S. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.07.004 · Cited by 56
Role of Receptors in Relation to Plaques and Tangles in Alzheimer’s Disease Pathology
Sharma, K., Pradhan, S., Duffy, L. K., Yeasmin, S., Bhattarai, N., & Schulte, M. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312987 · Cited by 59
Accumulation of APP-CTF induces mitophagy dysfunction in the iNSCs model of Alzheimer’s disease
Lee, S.-E., Kwon, D., Shin, N., Kong, D., Kim, N. G., Kim, H.-Y., Kim, M.-J., Choi, S. W., & Kang, K.-S. (2022) · Cell Death Discovery · doi:10.1038/s41420-021-00796-3 · Cited by 53
Lacour, M., Quenez, O., Rovelet‐Lecrux, A., Salomon, B., Rousseau, S., Richard, A., Quillard‐Muraine, M., Pasquier, F., Rollin‐Sillaire, A., Martinaud, O., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190193 · Cited by 54
Self-citationPorciúncula, L. O., Goto‐Silva, L., Ledur, P. F., & Rehen, S. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.674563 · Cited by 54
Symptomatic, Genetic, and Mechanistic Overlaps between Autism and Alzheimer’s Disease
Nadeem, M. S., Hosawi, S. B. I., Alshehri, S., Ghoneim, M. M., Imam, S. S., Murtaza, B. N., & Kazmi, I. A. (2021) · Biomolecules · doi:10.3390/biom11111635 · Cited by 60
Molecular Insight into the Therapeutic Promise of TargetingAPOE4for Alzheimer’s Disease
Mamun, A. A., Uddin, M. S., Bashar, M. F. B., Zaman, S., Begum, Y., Bulbul, I. J., Islam, M. S., Sarwar, M. S., Mathew, B., Amran, M. S., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5086250 · Cited by 54
Chang, J. L., Hinrich, A. J., Roman, B., Norrbom, M., Rigo, F., Marr, R. A., Norstrom, E. M., & Hastings, M. L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.029 · Cited by 53
Detecting Oxidative Stress Biomarkers in Neurodegenerative Disease Models and Patients
Sidorova, Y. A., & Domanskyi, A. (2020) · Methods and Protocols · doi:10.3390/mps3040066 · Cited by 50
Alkhalifa, A. E., Al-Ghraiybah, N. F., & Kaddoumi, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031914 · Cited by 52
The role of de novo mutations in adult-onset neurodegenerative disorders
Nicolas, G., & Veltman, J. A. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1939-3 · Cited by 53
Self-citationHajjo, R., Sabbah, D. A., Abusara, O. H., & Bawab, A. Q. A. (2022) · Diagnostics · doi:10.3390/diagnostics12122975 · Cited by 57
Mitochondria in Aging and Alzheimer’s Disease: Focus on Mitophagy
Pradeepkiran, J. A., Baig, J., Seman, A., & Reddy, P. H. (2023) · The Neuroscientist · doi:10.1177/10738584221139761 · Cited by 52
Garcez, M. L., Jacobs, K. R., & Guillemin, G. J. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00057-3 · Cited by 51
Characterization of the chromatin accessibility in an Alzheimer’s disease (AD) mouse model
Wang, Y., Zhang, X., Song, Q., Hou, Y., Liu, J., Sun, Y., & Wang, P. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00598-2 · Cited by 51
Epigenetics: Recent Advances and Its Role in the Treatment of Alzheimer's Disease
Xiao, X., Liu, X., & Jiao, B. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.538301 · Cited by 53
Ullah, R., & Lee, E. J. (2023) · Experimental Neurobiology · doi:10.5607/en23014 · Cited by 51
Stefanovski, L., Meier, J. M., Pai, R. K., Triebkorn, P., Lett, T. A. P., Martin, L., Bülau, K., Hofmann‐Apitius, M., Solodkin, A., McIntosh, A. R., et al. (2021) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2021.630172 · Cited by 47
Early- and Late-Onset Alzheimer’s Disease: Two Sides of the Same Coin?
Valdez-Gaxiola, C. A., Rosales-Leycegui, F., Gaxiola-Rubio, A., Moreno-Ortíz, J. M., & Figuera, L. E. (2024) · Diseases · doi:10.3390/diseases12060110 · Cited by 55
An update on the genetics of dementia with Lewy bodies
Vergouw, L. J. M., van Steenoven, I., van de Berg, W. D. J., Teunissen, C. E., Swieten, J. C. V., Bonifati, V., Lemstra, A. W., & de Jong, F. J. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.07.009 · Cited by 49
Hernández-Sapiéns, M. A., Reza-Zaldívar, E. E., Cevallos, R. R., Márquez-Aguirre, A. L., Gazarian, K. G., & Canales-Aguirre, A. A. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00151 · Cited by 46
Sidiropoulou, G. A., Metaxas, A., & Kourti, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1217730 · Cited by 54
Metadata
- Authors
- Lanoiselée, H.-M., Nicolas, G., Wallon, D., Rovelet-Lecrux, A., Lacour, M., Rousseau, S., Richard, A.-C., Pasquier, F., Rollin-Sillaire, A., Martinaud, O., Quillard-Muraine, M., de la Sayette, V., Boutoleau-Bretonniere, C., Etcharry-Bouyx, F., Chauviré, V., Sarazin, M., le Ber, I., Epelbaum, S., Jonveaux, T., Rouaud, O., Ceccaldi, M., Félician, O., Godefroy, O., Formaglio, M., Croisile, B., Auriacombe, S., Chamard, L., Vincent, J.-L., Sauvée, M., Marelli-Tosi, C., Gabelle, A., Ozsancak, C., Pariente, J., Paquet, C., Hannequin, D., Campion, D., & collaborators of the CNR-MAJ project
- Affiliations
- Inserm (FR)
- Centre Hospitalier Universitaire d'Angers (FR)
- Centre Hospitalier Sainte-Anne (FR)
- Centre National de la Recherche Scientifique (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- CHU Dijon Bourgogne (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Hospices Civils de Lyon (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Centre Hospitalier Universitaire de Grenoble (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Corresponding author
- Campion, Dominique
- ORCID
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-03-28
- Volume
- 14
- Issue
- 3
- Pages
- e1002270
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC5370101
- OpenAlex
- W2600872530
- Cited by
- 616
- References
- 44
- Citations by year
- 2026: 58 · 2025: 102 · 2024: 94 · 2023: 75 · 2022: 79 · 2021: 64 · 2020: 58 · 2019: 41 · 2018: 34 · 2017: 9
- FWCI
- 28.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion, cc-by)
- Funders
- Clinical Research Hospital Program from the French Ministry of Health (GMAJ 2008/067)
- French Ministry of Health (CNR-MAJ)
- European Union (JPND PERADES, ANR-13-JPRF-0001-04)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- early-onset Alzheimer's disease, APP mutations, PSEN1 mutations, PSEN2 mutations, presenilin, amyloid precursor protein, novel mutations, de novo mutations, sporadic Alzheimer's disease, familial Alzheimer's disease, genetic screening, variant interpretation, cerebrospinal fluid biomarkers, total tau, phosphorylated tau, amyloid-beta 42, genetic counseling, mutation carriers
- MeSH terms
- Adult, Alzheimer Disease, Female, France, Genetic Testing, Humans, Male, Middle Aged, Mutation, Amyloid beta-Protein Precursor, Age of Onset, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
